Pharma Focus Asia

Generative Adversarial Autoencoders to Revolutionize New Medications

An international group of computer scientists have developed a Generative Adversarial Autoencoders (AAE) for generating novel molecular finger prints with a defined set of parameters.

A 7 layer AAE architecture with the latent middle layer serving as a discriminator was developed. As an input and output the AAE uses a vector of binary fingerprints and concentration of the molecule.

In the latent layer, a neuron responsible for growth inhibition percentage was introduced. It indicates the reduction in the number of tumour cells after the treatment. To train the AAE, the NCI-60 cell line assay data for 6252 compounds profiled on MCF-7 cell line. The output of the AAE was used to screen 72 million compounds in PubChem and select candidate molecules with potential anti-cancer properties.

This approach is a proof of concept of an artificially-intelligent drug discovery engine, where AAEs are used to generate new molecular fingerprints with the desired molecular properties.

This could totally revolutionize how anticancer drugs are developed and they have built a deep learning neural network that can research and discover new formulas for medications.

All the millions of organic chemical substances used in anticancer drug protection are capable to understand with the development of a neural network. It also helps to figure out how to combine the molecules to form new drugs.

However, Pharmaceutical research is incredibly difficult – there are hundreds of millions of substances in inorganic chemistry, but only a tiny fraction of these substances are used in medicinal drugs.

Drug research involves creating a compound and then persisting to repeatedly change in the laboratory to change if it will be better or safer for human use.

The GAN System was developed in 2014 and it enables unsupervised machine learning by getting two neural networks to compete against each other to enhance the end result.

Modern DL techniques are structured as deep architectures, called Deep Neural Networks (DNNs). Because of this flexibility and adaptability of DNN for learning from large range of data, DNNs are now considered as an increasingly important area in the biomedical field that shows significant potential in comprehensive -omics analysis.

It could be useful for tackling many current issues. Most DL-based methods require a massive amount of data for their training, optimization and validation and are often applied in most data-rich fields of biomedical science.

magazine-slider-image
magazine-slider-image
Cytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024